ARTICLE | Clinical News
Interneuron starts trospium Phase III
September 6, 2001 7:00 AM UTC
IPIC began U.S. double-blind Phase III testing of trospium, a muscarinic receptor antagonist, to treat overactive bladder/urinary incontinence. The 12-week study will enroll 500 patients and will compare the reduction in micturition (urination) and incontinence episodes for trospium patients versus placebo. IPIC expects to submit an NDA for trospium by the end of 2002. ...